New Obesity Drug Tirzepatide Makes an Entrance
The key to Zepbound’s weight loss potential is its active ingredient, tirzepatide. This is the same ingredient found in the ...
Relationship Between Opioid Prescribing and Overdose Mortality
This paper provides an analysis of relationships between prescribing for opioid analgesics versus drug overdose mortality.
Politics & Business of Drug Imports
The Food and Drug Administration's approval of Florida’s plan to import drugs was made possible after Alex Azar certified it.
Extreme Cold is Bad for your Health
Prolonged exposure to freezing temperatures can lead to serious health conditions, with hypothermia being the most immediate concern.
An Impossible Choice
Is a doctor allowed to protect a patient's life when politicians believe the patient should be allowed to die?
Pain Upon Pain
The Emergency Department is supposed to be a place where patients receive critical care. For many, it's a place of ...
Patient Social Networks
A patient's social network is often a literal life line for improving patient compliance and long term outcomes.
How I Found My Doctor
Obtaining an accurate diagnosis is the first and most important step to acquiring the best outcome in a patient’s health ...
Tracking the 2023-2024 Flu Season
From October 1, 2023, through December 30, 2023, the CDC tracked flu-related cases that have impacted public health.
The Fault in Our Tests
We share our proposal to collaborate with the AAMC to study the nature of implicit biases in the MCAT and ...
We Need Open Artificial Intelligence
Some people are saying AI will destroy the world, but I think it contributes to the hope of saving the ...
My Dying Wish
I encourage everybody to have a hard discussion with your family and close friends on the subject of dying.
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more